Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis.

Trial Profile

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 15 Jan 2015 Planned primary completion date changed to 1 Oct 2015, according to ClinicalTrials.gov record.
    • 15 Jan 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 23 Jan 2014 Planned number of patients changed from 10 to 8 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top